The therapeutic potential of human umbilical mesenchymal stem cells from wharton’s jelly in the treatment of rat peritoneal dialysis-induced fibrosis

Stem Cells Translational Medicine

Volumn 5, Issue 2, 2016, Pages 235-247

  Fan, Yu Pei ^a   Hsia, Ching Chih ^b   Tseng, Kuang Wen ^c   Liao, Chih Kai ^d   Fu, Tz Win ^e   Ko, Tsui Ling ^f   Chiu, Mei Miao ^a,c   Shih, Yang Hsin ^g,h   Huang, Pei Yu ⁱ   Chiang, Yi Chia ^j   Yang, Chih Ching ^k,l,m   Fu, Yu Show ^b,m  

^a Institute of Anatomy and Cell Biology   (Taiwan)

^b TAIPEI CITY HOSPITAL   (Taiwan)

^c MACKAY MEDICAL COLLEGE   (Taiwan)

^d I SHOU UNIVERSITY   (Taiwan)

^e Laboratory Medicine   (Taiwan)

^f SHU ZEN COLLEGE OF MEDICINE AND MANAGEMENT   (Taiwan)

^g TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^h TAIPEI MEDICAL UNIVERSITY   (Taiwan)

ⁱ Institute of Physiology   (Taiwan)

^j Taipei Jing Mei Girls High School   (Taiwan)

^k Ministry of Health and Welfare   (Taiwan)

^l Department of Internal Medicine ^*  (Taiwan)

^m NATIONAL YANG MING UNIVERSITY   (Taiwan)

more..

Author keywords

Mesenchymal stem cells; Peritoneal dialysis; Peritoneal fibrosis induced by dialysis; Submesothelial thickening; Transplantation; Umbilical cord

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; METHYLGLYOXAL; PERITONEAL DIALYSIS FLUID; TRANSFORMING GROWTH FACTOR BETA; ACTIN; BIOLOGICAL MARKER; CULTURE MEDIUM; FIBRONECTIN; SMOOTH MUSCLE ACTIN, RAT;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PARAMETERS; CELL CULTURE; CELL DAMAGE; CELL DEATH; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN UMBILICAL MESENCHYMAL STEM CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MESENCHYMAL STEM CELL; NONHUMAN; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERMEABILITY; POSITRON EMISSION TOMOGRAPHY; RAT; ULTRAFILTRATION; WESTERN BLOTTING; WHARTON JELLY; XENOGRAFT; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; CYTOLOGY; DISEASE MODEL; EPITHELIUM CELL; GENE EXPRESSION; GENETICS; GRAFT SURVIVAL; INTRAPERITONEAL DRUG ADMINISTRATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PERITONEUM; PHYSIOLOGY; SPRAGUE DAWLEY RAT; UMBILICAL CORD;

ACTINS; ANIMALS; BIOMARKERS; CELL DEATH; CULTURE MEDIA; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; FIBRONECTINS; GENE EXPRESSION; GRAFT SURVIVAL; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; NEOVASCULARIZATION, PATHOLOGIC; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONEUM; PYRUVALDEHYDE; RATS; RATS, SPRAGUE-DAWLEY; TRANSPLANTATION, HETEROLOGOUS; UMBILICAL CORD; WHARTON JELLY;

EID: 84969429633     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2015-0001     Document Type: Article

References (70)

1. Davies SJ, Bryan J, Phillips L et al. Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996;11:498-506.
2. Mateijsen MA, van der Wal AC, Hendriks PM et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999;19:517-525.
3. Davies SJ. Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int 2004;66:2437-2445.
4. Flessner MF. The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol 2005;288:F433-F442.
5. Williams JD, Craig KJ, Topley N et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002;13:470-479.
6. Devuyst O, Margetts PJ, Topley N. The pathophysiology of the peritoneal membrane. J Am Soc Nephrol 2010;21:1077-1085.
7. Kawaguchi Y, Ishizaki T, Imada A et al. Searching for the reasons for drop-out from peritoneal dialysis: A nationwide survey in Japan. Perit Dial Int 2003;23(suppl 2):S175-S177.
8. De Vriese AS, Flyvbjerg A, Mortier S et al. Inhibition of the interaction of AGE-RAGE pre- vents hyperglycemia-induced fibrosis of the peritoneal membrane. J Am Soc Nephrol 2003;14:2109-2118.
9. Williams JD, Topley N, Craig KJ et al. The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004;66: 408-418.
10. Selgas R, Fernandez-Reyes MJ, Bosque E et al. Functional longevity of the human perito- neum: how long is continuous peritoneal dialysis possible? Results of a prospective medium long- term study. Am J Kidney Dis 1994;23:64-73.
11. del Peso G, Fernández-Reyes MJ, Hevia C et al. Factors influencing peritoneal transport parameters during the first year on peritoneal dialysis: Peritonitis is the main factor. Nephrol Dial Transplant 2005;20:1201-1206.
12. De Vries AS, Mortier S, Lameire NH. What happens to the peritoneal membrane in long-term peritoneal dialysis? Perit Dial Int 2001; 21:9-18.
13. Loureiro J, Aguilera A, Selgas R et al. Blocking TGF-b1 protects the peritoneal membrane from dialysate-induced damage. J Am Soc Nephrol 2011;22:1682-1695.
14. Chen YT, Chang YT, Pan SY et al. Lineage tracing reveals distinctive fates for mesothelial cells and submesothelial fibroblasts during peritoneal injury. J Am Soc Nephrol 2014;25: 2847-2858.
15. Kihm LP, Müller-Krebs S, Klein J et al. Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis. J Am Soc Nephrol 2011;22:914-926.
16. Fang CC, Yen CJ, Chen YM et al. Diltiazem suppresses collagen synthesis and IL-1beta- induced TGF-beta1 production on human peritoneal mesothelial cells. Nephrol Dial Transplant 2006;21:1340-1347.
17. Io H, Hamada C, Ro Y et al. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 2004;65:1927-1936.
18. Seo GS. [Stem cell properties of therapeutic potential]. Korean J Gastroenterol 2011;58: 125-132.
19. Wang N, Li Q, Zhang L et al. Mesenchymal stem cells attenuate peritoneal injury through secretion of TSG-6. PLoS One 2012;7:e43768.
20. Ueno T, Nakashima A, Doi S et al. Mesenchymal stem cells ameliorate experimental peritoneal fibrosis by suppressing inflammation and inhibiting TGF-b1 signaling. Kidney Int 2013;84:297-307.
21. Mitchell KE, Weiss ML, Mitchell BM et al. Matrix cells from Wharton’s jelly form neurons and glia. STEM CELLS 2003;21:50-60.
22. Fu YS, Shih YT, Cheng YC et al. Transformation of human umbilical mesenchymal cells into neurons in vitro. J Biomed Sci 2004;11: 652-660.
23. Wang HS, Hung SC, Peng ST et al. Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. STEM CELLS 2004;22: 1330-1337.
24. Fu YS, Cheng YC, Lin MY et al. Conversion of human umbilical cord mesenchymal stem cells in Wharton’s jelly to dopaminergic neurons in vitro: Potential therapeutic application for Parkinsonism. STEM CELLS 2006;24:115-124.
25. Yang CC, Shih YH, Ko MH et al. Transplantation of human umbilical mesenchymal stem cells from Wharton’s jelly after complete transection of the rat spinal cord. PLoS One 2008; 3:e3336.
26. Lin YC, Ko TL, Shih YH et al. Human umbilical mesenchymal stem cells promote recovery after ischemic stroke. Stroke 2011;42:2045-2053.
27. Tsai PC, Fu TW, Chen YM et al. The therapeutic potential of human umbilical mesenchymal stem cells from Wharton’s jelly in the treatment of rat liver fibrosis. Liver Transpl 2009;15:484-495.
28. Hirahara I, Kusano E, Yanagiba S et al. Peritoneal injury by methylglyoxal in peritoneal dialysis. Perit Dial Int 2006;26:380-392.
29. Hansen-Smith FM, Watson L, Lu DY et al. Griffonia simplicifolia I: Fluorescent tracer for microcirculatory vessels in nonperfused thin muscles and sectioned muscle. Microvasc Res 1988;36:199-215.
30. Twardowski ZJ, Nolph KO, Khanna R et al. Peritoneal equilibration test. Perit Dial Int 1987; 7:138-148.
31. Lai KN, Ho SK, Leung J et al. Increased survival of mesothelial cells from the peritoneum in peritoneal dialysis fluid. Cell Biol Int 2001; 25:445-450.
32. Okabe E, Tomo T, Tezono K et al. Synergistic cytotoxicity of acidity and glucose degradation products in peritoneal dialysis fluid. J Artif Organs 2004;7:155-160.
33. Schwenger V, Morath C, Salava A et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006;17:199-207.
34. Witowski J, Wisniewska J, Korybalska K et al. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001;12:2434-2441.
35. Wieslander AP, Andr én AH, Nilsson-Thorell C et al. Are aldehydes in heat-sterilized peritoneal dialysis fluids toxic in vitro? Perit Dial Int 1995;15:348-352.
36. Witowski J, Korybalska K, Wisniewska J et al. Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000;11:729-739.
37. Amore A, Cappelli G, Cirina P et al. Glucose degradation products increase apoptosis of human mesothelial cells. Nephrol Dial Transplant 2003;18:677-688.
38. Noh H, Kim JS, Han KH et al. Oxidative stress during peritoneal dialysis: Implications in functional and structural changes in the membrane. Kidney Int 2006;69:2022-2028.
39. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000;342:1350-1358.
40. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-1292.
41. Krediet RT. The peritoneal membrane in chronic peritoneal dialysis. Kidney Int 1999;55: 341-356.
42. Margetts PJ, Bonniaud P. Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int 2003;23:530-541.
43. Margetts PJ, Bonniaud P, Liu L et al. Transient overexpression of TGF-beta1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 2005;16:425-436.
44. Margetts PJ, Kolb M, Galt T et al. Gene transfer of transforming growth factor-b1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol 2001;12:2029-2039.
45. Struijk DG, van der Reijden HJ, Krediet RT et al. Effect of phosphatidylcholine on peritoneal transport and lymphatic absorption in a CAPD patient with sclerosing peritonitis. Nephron 1989;51:577-578.
46. Hür E, Bozkurt D, Sipahi S. Octreotide may prevent ultrafiltration failure in experimental peritonitis model. Turk Nephrol Dial Transpl 2011;20:46-52.
47. Guo QY, Peng WX, Cheng HH et al. Hyaluronan preserves peritoneal membrane transport properties. Perit Dial Int 2001;21:136-142.
48. Schilte MN, Loureiro J, Keuning ED et al. Long-term intervention with heparins in a rat model of peritoneal dialysis. Perit Dial Int 2009; 29:26-35.
49. Grzegorzewska AE. Protecting the peritoneal membrane in dialyzed patients. Adv Med Sci 2006;51:191-196.
50. Li J, Guo ZY, Gao XH et al. Low molecular weight heparin (LMWH) improves peritoneal function and inhibits peritoneal fibrosis possibly through suppression of HIF-1a, VEGF and TGF-b1. PLoS One 2015;10:e0118481.
51. Saglam F, Cavdar Z, Sarioglu S et al. Pioglitazone reduces peritoneal fibrosis via inhibition of TGF-b, MMP-2, and MMP-9 in a model of encapsulating peritoneal sclerosis. Ren Fail 2012; 34:95-102.
52. Nie J, Dou X, Hao W et al. Smad7 gene transfer inhibits peritoneal fibrosis. Kidney Int 2007;72:1336-1344.
53. Ro Y, Hamada C, Inaba M et al. Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrol Dial Transplant 2007;22: 2838-2848.
54. Yoshizawa H, Morishita Y, Watanabe M et al. TGF-b₁-siRNA delivery with nanoparticles inhibits peritoneal fibrosis. Gene Ther 2015;22: 333-340.
55. Schalkwijk CG, Posthuma N, ten Brink HJ et al. Induction of 1,2-dicarbonyl compounds, intermediates in the formation of advanced glycation end-products, during heat-sterilization of glucose-based peritoneal dialysis fluids. Perit Dial Int 1999;19:325-333.
56. Bierhaus A, Schiekofer S, Schwaninger M et al. Diabetes-associated sustained activation www.StemCellsTM.com of the transcription factor nuclear factor-kappaB. Diabetes 2001;50:2792-2808.
57. Basta G, Lazzerini G, Massaro M et al. Advanced glycation end products activate endo- thelium through signal-transduction receptor RAGE: A mechanism for amplification of inflammatory responses. Circulation 2002;105:816-822.
58. Lawrence T, Gilroy DW, Colville-Nash PR et al. Possible new role for NF-kappaB in the resolution of inflammation. Nat Med 2001;7: 1291-1297.
59. Nie J, Hao W, Dou X et al. Effects of Smad7 overexpression on peritoneal inflammation in a rat peritoneal dialysis model. Perit Dial Int 2007; 27:580-588.
60. Inagi R, Miyata T, Yamamoto T et al. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: Role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 1999;463:260-264.
61. Nakamoto M. Pathogenesis of peritoneal fibrosis and peritoneal small vessel changes. Perit Dial Int 1996;16(suppl 1):S39-S41.
62. Zhao DC, Lei JX, Chen R et al. Bone marrow-derived mesenchymal stem cells protect against experimental liver fibrosis in rats. World J Gastroenterol 2005;11:3431-3440.
63. Ninichuk V, Gross O, Segerer S et al. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney Int 2006;70:121-129.
64. Tülpar S, Poyrazoğlu MH, Özbilge H et al. Modulation of inflammation by mesenchymal stem cell transplantation in peritoneal dialysis in rats. Ren Fail 2012;34:1317-1323.
65. Wang N, Shao Y, Mei Y et al. Novel mechanism for mesenchymal stem cells in attenuating peritoneal adhesion: accumulating in the lung and secreting tumor necrosis factor a-stimulating gene-6. Stem Cell Res Ther 2012;3:51.
66. Yu MA, Shin KS, Kim JH et al. HGF and BMP-7 ameliorate high glucose-induced epithelial-to-mesenchymal transition of peritoneal mesothelium. J Am Soc Nephrol 2009;20:567-581.
67. Hwang JH, Shim SS, Seok OS et al. Comparison of cytokine expression in mesenchymal stem cells from human placenta, cord blood, and bone marrow. J Korean Med Sci 2009;24: 547-554.
68. Tang KH, Ma S, Lee TK et al. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology 2012;55:807-820.
69. van den Broek LJ, Kroeze KL, Waaijman T et al. Differential response of human adipose tissue-derived mesenchymal stem cells, dermal fibroblasts, and keratinocytes to burn wound exudates: Potential role of skin-specific chemokine CCL27. Tissue Eng Part A 2014;20: 197-209.
70. Ohta S, Misawa A, Fukaya R et al. Macrophage migration inhibitory factor (MIF) promotes cell survival and proliferation of neural stem/progenitor cells. J Cell Sci 2012;125: 3210-3220.